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Abstract
Human ERBB2 is a proto-oncogene that codes for the erbB-2 epithelial growth factor receptor. In human breast cancer
(HBC), erbB-2 protein overexpression has been repeatedly correlated with poor prognosis. In more recent works,
underexpression of this gene has been described in HBC. Moreover, it is also recognised that oncogenes that are commonly
amplified or deleted encompass point mutations, and some of these are associated with HBC. In cat mammary lesions
(CMLs), the overexpression of ERBB2 (27%–59.6%) has also been described, mostly at the protein level and although cat
mammary neoplasias are considered to be a natural model of HBC, molecular information is still scarce. In the present work,
a cat ERBB2 fragment, comprising exons 10 to 15 (ERBB2_10–15) was achieved for the first time. Allelic variants and genomic
haplotype analyses were also performed, and differences between normal and CML populations were observed. Three
amino acid changes, corresponding to 3 non-synonymous genomic sequence variants that were only detected in CMLs,
were proposed to damage the 3D structure of the protein. We analysed the cat ERBB2 gene at the DNA (copy number
determination), mRNA (expression levels assessment) and protein levels (in extra- and intra protein domains) in CML
samples and correlated the last two evaluations with clinicopathological features. We found a positive correlation between
the expression levels of the ERBB2 RNA and erbB-2 protein, corresponding to the intracellular region. Additionally, we
detected a positive correlation between higher mRNA expression and better clinical outcome. Our results suggest that the
ERBB2 gene is post-transcriptionally regulated and that proteins with truncations and single point mutations are present in
cat mammary neoplastic lesions. We would like to emphasise that the recurrent occurrence of low erbB-2 expression levels
in cat mammary tumours, suggests the cat mammary neoplasias as a valuable model for erbB-2 negative HBC.
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Introduction
Several aspects contribute to the value of domestic animals as
models for human cancers [1,2]. Also, it is generally recognised
that the use of animal models for the safety testing of
investigational drugs is imperfect and needs more accurate
(predictive) preclinical animal model screening that has the
potential to increase the pace and reduce the cost of successful
drug development for breast cancer [3]. Similarities in both
histology and biological behaviour support the idea of cat
mammary primary malignant lesions (MaLs) as a possible model
to study HBC [4]. In fact, several authors consider that
spontaneous cat mammary pre-invasive intraepithelial lesions
(hyperplasias and neoplasias) and malignant lesions share the full
spectrum of morphological features with their human counterparts
[2–5]. The annual incidence of cat mammary neoplasia has been
estimated at 12.8–25.4 per 100.000 female cats, and mammary
malignant neoplasia represents an important cause of cat
mortality. The incidence and morbidity of these tumours have
been demonstrated to be very high due to their rapid growth, high
proliferation rates, and capability to metastasise to regional lymph
nodes and distant organs [6–9].
The pathogenesis and progression of invasive breast cancer
have been related to a large variety of growth factors, and the
proteins of the epithelial growth factor receptor family have been
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the most investigated in this heterogeneous disease [10,11]. The
EGFR family includes four receptors: EGFR (or ERBB1), ERBB2
(also known as NEU, EGFR2 or HER2), ERBB3, and ERBB4 [12–
15]. These receptors share an overall structure with an extracel-
lular region, a transmembrane region and an intracellular
carboxy-terminal tail that contains a tyrosine autophosphorylation
site [16,17]. The activation of oncogenes by mutation or copy
number gain (DNA amplification), along with the loss ofactivity of
tumour suppressor genes by mutation or copy loss, are somatic
alterations of the genome that result in tumour initiation [18–20].
Also, it is highly recognised that acquired somatic mutations are
responsible for approximately 90% of breast tumours [21]. In
summary, genes that are commonly amplified or deleted often
include point mutations that activate or inactivate the oncogenes
[22,23]. It is important to point out that the activation of
oncogenes, such as ERBB2, provides an opportunity to develop
therapeutic targets of the affected protein itself or for a
downstream event [20]. The monoclonal antibody trastuzumab
(HerceptinH), which targets the activated oncogenic forms of erbB-
2 protein and acts as a kinase inhibitor, was developed and
approved for use as an HBC treatment [24–27].
In recent years, a systematic investigation of the potential role of
inherited germline variants of ERBB2 in breast cancer risk has
been conducted using single nucleotide variants and haplotype-
based analyses [28–32]. The most notable overall observation in
this investigation is the lack of evidence to support a significant
association between ERBB2 genomic sequence variants (SVs) and
HBC initiation, despite the wealth of information supporting its
role in breast cancer progression [16,31,32]. Concerning the
determination of breast cancer prognosis, it has recently been
suggested that the quantification of ERBB2 mRNA transcripts by
qRT-PCR should be applied to the routine erbB-2 IHC
procedures as an additional molecular test [33,34]. In previous
studies, the authors state that a fraction of human breast cancers
[35–37] and cat mammary lesions [38] show a good correlation
between high expression levels of ERBB2 mRNA and the erbB-2
protein. In more recent works, low ERBB2 RNA expression levels
have been described in HBC, suggesting the underexpression of
this gene [39–40]. In cat mammary lesions, alterations of the
ERBB2 proto-oncogene have been studied, mostly at the protein
level, and, as occurs in HBC, the overexpression of the erbB-2
protein has been recognised to confer poor prognoses to CMLs
[4,38,41–43]. Although cat mammary neoplasias are considered to
be a natural model of human breast cancer, molecular information
on benign and malignant lesions, particularly regarding the cat
ERBB2 gene and erbB-2 protein, is still scarce [44].
In the present work, we characterised the cat ERBB2 gene in
normal samples and cat mammary lesion samples by different
approaches in order to obtain novel information concerning the
ERBB2 gene in the cat mammary tumour system (genome and
proteome). Our study focuses on the cat ERBB2 DNA fragment
from exon 10 to 15 (ERBB2_10-15), which codes for the part of the
extracellular domain of the erbB-2 protein that is targeted by the
therapeutic antibody trastuzumab (HerceptinH).
The present analysis includes a collection of non-neoplastic and
neoplastic lesions that represent a morphologically and clinico-
pathologically heterogeneous group of samples. Different ap-
proaches were employed, such as comparative studies of the cat
ERBB2 DNA sequence with its human counterpart, sequence
variant characterisation, DNA and mRNA status evaluation by
qRT-PCR, protein level quantification by immunohistochemistry
(with two different antibodies), in silico coding sequence and
respective translated protein construction, and determination of
the consequences of the identified exonic non-synonymous
sequence variants (nsSVs) in the cat erbB-2 3D structure. We
also analysed and correlated the results obtained by these different
techniques with the clinicopathological traits of the cat mammary
neoplastic and non-neoplastic lesion samples.
Results
A total of 43 cat mammary lesion samples and 23 normal
samples (14 blood and 9 normal mammary gland samples) were
collected for this work. All of the cat mammary lesions analysed in
the present work were clinically and histologically characterised
(Table S1). They included a collection of non-neoplastic and
neoplastic lesions that represented a morphologically and clinico-
pathologically heterogeneous group of samples and were obtained
over a two-year follow-up period (in the case of queens bearing
malignant tumours). For statistical purposes, we established a
tumour scale for clinical and histological grading and prognostic
factors (Table S2).
Analysis of the cat ERBB2_10/15 fragment in normal
samples
The cat ERBB2 DNA fragment from exon 10 to 15 was
amplified by polymerase chain reaction (PCR) with primers E10
and E15, using genomic DNA obtained from normal samples
(blood) as template. After cloning and sequencing the amplified
fragment, a final cat gDNA ERBB2_10/15 consensus sequence of
2173 bp was obtained. The gDNA ERBB2_10/15 sequence
showed an incomplete alignment with the cat ERBB2 RNA
sequence (GenBank: AY702651.1), the cat Ensembl GeneScaffold
1508 and LGD gene-2064 (an ERBB2 gene in the Genome
Annotation Resource Field (GARField browser; Felis catus v12.2).
Additionally, high similarity was detected between cat ERBB2_10/
15 and its human counterpart (GenBank: NG007503; Figure S1).
These preliminary result allowed us to recognise a de novo, 84 nt
sequence (from 315–398 nt, comprising part of intron 11) and to
identify the exon boundaries in the cat ERBB2_10/15 sequence
(Figure 1).
Sequence variant detection and prediction of coding
regions and protein sequence
To search for ERBB2_10/15 sequence variants, two fragments,
approximately 1300 bp (primers E10/E14) and 1500 bp (primers
E12/E15) in length, were amplified by PCR. The sequences
obtained from 14 normal gDNA samples (extract from blood
samples) were multi-aligned, and a final consensus sequence was
established (2173 bp), submitted to GenBank (reference
JQ284376), and used in the present work as the reference or
wild-type (wt) DNA sequence (cat ERBB2_10-15 sequence; Figure
S1). All the sequences obtained for normal sample were multi-
aligned with the ERBB2_10-15 wt sequence and 21 SVs were
detected (Figure 1 and Table S3).
The same procedures were applied to the 19 gDNAs extracted
from the CMLs, including 2 benign non-neoplastic (hyperplasia), 2
benign neoplastic, 12 primary malignant (MaL) and 3 metastatic
lesions. The ERBB2_10/15 wt sequence was multi-aligned with
the sequences obtained for each CML and 24 SVs were identified
(Figure 1 and Table S3).
Some interesting results were obtained in the analysis of the 30
SVs detected, such as the fact that some SVs were only detected in
one type of CMLs (Table S3). Moreover, the in silico physical
mapping of the genomic sequence variations showed 7 SVs in
exonic positions; two were synonymous variations (g.1025T.C
and g.1128T.C) and 5 were non-synonymous variations (nsSVs;
Table 1 and Table S3). Furthermore, from the 5 nsSVs, 1 was only
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detected in the normal samples (g.226 G.A) and 4 were only
detected in the mammary lesion samples (Table S3).
Also, from the total SVs observed (30 SVs), the normal samples
showed a much lower frequency of variant alleles (12.77%) and
heterozygous condition (16.98%) compared to the CMLs (Table
S3). In the CMLs the percentage of variant alleles was highest for
the benign lesions (18.64%) and similar between the primary
malignant and metastatic samples. Moreover, the frequency of the
heterozygous condition, was lowest for the MeLs (12.82%) in
comparison with the BeLs (20.75%) and MaLs (20.41%) (Table
S3).
Determination of Hardy-Weinberg equilibrium, genotype
association and genomic haplotype
With respect to all of the allelic variants detected, 10 loci showed
deviations from Hardy–Weinberg equilibrium (p,0.05; Table S3).
Basic single allelic and genotypic models of association were used
to evaluate the allelic frequency differences between normal and
mammary lesions (significant p value ,0.05). With the single
allelic association test, 5 variants showed significant values of
association with the CMLs under analysis: g.355G.A,
g.1914G.C, g.2037G.C, g.2041A.C and g.2065T.C. Four
of the last 5 also showed significant values of genotypic association
with the mammary lesions group: g.1914G.C, g.2037G.C,
g.2041A.C and g.2065T.C (Table S3).
The common haplotypes (frequency higher than 5%) were
independently determined for three groups of samples: normal
samples, CML samples and total samples (Table 1). In general,
there was evidence of a strong linkage disequilibrium (LD)
between SVs (no random association in the genotypes). The
second most frequent haplotype in the normal samples (haplotype
2; Table 1) corresponded to the reference sequence (GenBank:
JQ284376). It was also evident that the normal samples showed a
distinct haplotype categorisation (haplotype 1–9; Table 1) in
comparison with the CML samples (haplotype 10–19; Table 1).
Probable structural damage effects, homology modelling
and molecular dynamics studies of wild-type and variant
cat erbB-2 protein
The wild-type ERBB2_10/15 (CDS ERBB2_10/15) and variant
ERBB2_10/15 (CDS ERBB2_10/15_SV) coding sequences were
in silico constructed, and the respective reference (erbB-2_10/15)
and variant (erbB-2_10/15_SV) protein sequences were subse-
quently obtained (Figure S2 and Figure S3). A similarity of 98%
was found between these two protein sequences. The search for
the cat erbB-2_10/15 protein, using the NCBI BLASTP tool,
showed a high similarity with cat GenBank: NP_001041628.1
(99%) and with human GenBank: AAO18082.1 (92%) sequences.
The probable damaging effects of the 5 amino acid changes
identified in the present work, at the three-dimensional (3D)
protein structural level, were evaluated by software analysis using
Polyphen, Polyphen-2 and Pymol (Table S4). The five AA changes
analysed were: Arg46Lys, Val47Glu, Ala205Pro, His206Pro, and
Val214Ala. The software results demonstrated that the Arg46Lys
and Ala205Pro changes were benign modifications. However, the
remaining three amino acid changes (Val47Glu, His206Pro and
Val 214Ala) were classified as probably damaging to the 3D
structure of the protein.
In order to complete the homology modelling and molecular
dynamics studies, a complete wild-type cat erbB-2 homology
model was prepared using the human erbB-2 structure as a
template. The alignment of both structures revealed a near perfect
fit, with a root mean square deviation of 0.073 A˚ (Figure 2a).
The extracellular domains of the wild-type cat erbB-2 and the 5
variant homology models were then subjected to simulated
annealing (SA) tests, and the obtained structures were superim-
posed onto the initial wt cat erbB-2 homology model. In the SA
tests, a considerable rearrangement of the H-bond network with
the formation of new H-bonds was detected when comparing wild-
type Val47 and variant Glu47 (Figure 2b). Specifically, 2 H-bonds
were formed between key residues involved in the CR1/L2
domain interactions: Arg49:Glu54 and Arg51:Glu54 (Figure 2b).
Compared to the wild-type protein, the SA simulations performed
with the Arg46Lys change showed only minor adjustments
Figure 1. In silico physical map of cat ERBB2 gene from exons 10 to 15 (ERBB2_10–15). Physical mapping of exons 10 to 15 (red arrows) and
the de novo sequence genomic DNA (blue arrow; 84nt from 315–398 bp) corresponding to part of intron 11 of the cat ERBB2 gene. The position of
the four primers are point out in black arrows. The sequence variants detected in the present work are illustrated by its position nucleotide number
and a black asterisk. The distribution of the genomic SVs detected is not homogeneous and they are predominantly localized in intron 11.
doi:10.1371/journal.pone.0083673.g001
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observed in the H-bond network and no significant conforma-
tional rearrangements were observed in the protein backbone (L2
extracellular domain) (Figure 2c and Table S4).
The SA tests for the remaining 3 variants were not conclusive,
as it was impossible to superimpose the wt sequence with the
variants. This was probably due to the flexibility observed in the
CR2 domain, where the 3 mutations were located (Figure 2).
However, a straightforward comparative analysis between the wt
and variant 3D amino acid structures showed that the His206Pro
change conferred a polar to non-polar modification in the side
chain, and it also changed the residue side chain volume, which
could produce a change in the accessible surface propensity of the
cat erbB-2_10/15 protein structure. Additionally, the Val214Ala
change modified the side chain volume and resulted in the closest
contact with the surrounding chains (Table S4)
To improve the comparative analysis between the cat and
human protein variants, an extensive search was performed
considering all of the non-synonymous polymorphisms described
in the dbSNP database (NCBI) for the ERBB2 cDNA fragment
from exon 10–15, corresponding to the cat ERBB2 reference
sequence (GenBank: JQ284376). None of the corresponding AA
changes observed in the database had the exact position of the AA
changes detected in the present work (data not shown).
Immunohistochemistry (IHC) erbB-2 protein
quantification
For each anti-human erbB-2 antibody used, one specific for the
internal domain (CB11/int) and one specific for the external
domain (CBE356/ext), the immunoreactivity was assessed accord-
ing to the Hercep-Test guidelines as described in ASCO
recommendations [45]. The two anti-human erbB-2 antibodies
used were validated for cat species by western blotting onto cat
mammary protein extracts from frozen samples (in RNAlatter
solution) (Figure S4). Both antibodies recognized the expected
erbB-2 oncoprotein of 185 kDa.
In accord with the strength of immunostaining, the samples
scored as 0 or + were considered negative, whereas those scored as
++ or +++ were considered erbB-2 positives. The IHC scores and
erbB-2 negative or positive results described in this subsection are
shown in detail in additional table S5, and the IHC results are
summarise in figures 3 and 4.
Consistently, the IHC patterns of the erbB-2 protein revealed a
disparity in the membrane labelling between the two antibodies.
Of the 4 normal mammary tissues studied, 3 were obtained from 2
cats with hyperplasia in a different mammary gland (Table S1:
BeL5 and BeL6). Additionally, 8 residual normal mammary glands
peripheral to affected mammary tissues (Table S1: MaLs6, 10, 14,
17, 18, 20, 21 and MeL4) were used in the present study.
Moderate (erbB-2 ++) or strong (erbB-2 +++) IHC membrane
labelling was observed in 66.7% of normal samples for the
CBE356/ext antibody and in 91.7% of normal samples for the
CB11/int antibody (Figure 3a, b and Figure 4). Also, when we
compared the CBE356/ext with CB11/int results, the staining
intensities concordance revealed was 50%.
For both antibodies, the CMLs showed a lower percentage of
erbB-2 positive tissues than the normal samples. The percentage of
Figure 2. 3D models of wild-type and variant cat ErB-2_10-15 protein. (a) Superimposed extracellular domain of human erbB-2 (orange) and
wt cat erbB-2 homology model (yellow). Residues where mutations were observed are labelled. (b) Superimposed conformation of the wt (yellow)
and Val47Glu variant (green) cat erbB-2 homology model. (c) Superimposed conformation of the wt (yellow) and Arg46Lys variant (green) cat erbB-2
homology model. Structures are represented in cartoon format and H-bonds are represented in traced line using the respective structure colour
code.
doi:10.1371/journal.pone.0083673.g002
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positive CMLs was lower for CBE356/ext than for CB11/int
labelling (Figure 4 and Table S5). When the IHC results were
compared, the scores concordance was higher for the erbB-2
negative (48.48%) than for the positive (27.27%) CMLs samples.
The concordance of the two antibody labelling scores was 50%
in the BLs, 23.5% in the MaLs, and 41.7% in the MeLs. The
benign lesions revealed a notable incidence of moderate to strong
membrane labelling for both antibodies (Figure 3c-f and Figure 4).
The primary malignant lesions demonstrated the lowest frequency
of erbB-2 positive samples (Figure 3g-j and Figure 4). Of the three
lesion types, the MeLs were the least erbB-2 positive. In fact, none
of the systemic metastatic samples presented erbB-2 positive results
for the CBE356/ext antibody (Figure 4 and Table S5).
Comparing the IHC results from the normal mammary tissues
and the matching primary mammary lesions, the staining
intensities were concordant in only 9.09% for the CB11/int
antibody and 27.27% for the CBE356/ext antibody. The normal
samples showed an identical percentage of erbB-2 positive scores
compared with the corresponding benign lesions. Relative to the
matching primary malignant samples, a markedly higher labelling
score was observed in the normal samples for both antibodies. It
was only possible to compare the IHC scores of the normal tissue
adjacent to 1 mammary lymph node metastasis (Figure 3k, l),
which showed high protein scores for both antibodies (erbB-2
positive: MeL +++ and matching normal ++).
In order to verify whether erbB-2 positive is correlated with cat
ERBB2 gene amplification we subjected a total of 20 samples to
real time quantitative PCR (qPCR) for gene copy number
evaluation. The selection of the 20 samples was as follow: 10
Figure 3. Immunohistochemical evaluation of erbB-2 in cat
normal mammary tissues and in mammary gland lesions.
Normal samples (a; b), hyperplasic lesions (c; d) and neoplastic benign
lesions (e; f) showing strong and complete membrane labelling (score
3+) with the two antibodies used in IHC test: CB11/int and CBE356/ext.
Tubulopapillary lesions depicting 1+ score for HIC CBE356/ext staining
(g) and no labeling with CB11/int staining (h). Cribiform lesions with
moderate and complete membrane labelling (2+) for CBE356/ext
antibody (i) and 3+ score for CB11/int antibody (j). Lymph node
mammary metastatic lesion depicting 3+ scores for both antibodies (k;
l). Images original magnifications 4006 (a; b; i-l); 406 (c; d); 1006 (e;
f); 2006 (g; h). (g9-l9) 3006 amplification of the image highlight by
white squares in the correspondent (g-l).
doi:10.1371/journal.pone.0083673.g003
Figure 4. Percentage of immunohistochemistry erbB-2 posi-
tives samples. Percentage of HIC erbB-2 positive samples in the
different groups of samples. The Results show in outer ring correspond
to extracellular antibody (CBE356/ext) and in the inner ring correspond
to intracellular antibody (CB11/int).
doi:10.1371/journal.pone.0083673.g004
The Cat as Model for erbB-2-Negative HBC
PLOS ONE | www.plosone.org 6 December 2013 | Volume 8 | Issue 12 | e83673
normal and 10 mammary lesions (4, erbB-2 positive; 5, erbB-2
negative; and 1, erbB-2 positive for CBE356 and erbB-2 negative
for CB11) (Figure S5). In all cases we didn’t detect any gene
amplification.
RT-qPCR ERBB2 RNA expression analysis
We evaluated the RNA expression status of the ERBB2 gene in
five disease-free mammary samples (normal), four benign lesion
samples (3 hyperplasias and 1 neoplastic), fourteen primary
malignant lesion samples and five metastatic lesion samples
(Figure 5 and Table S1). Our results demonstrated the presence
of high ERBB2 RNA expression rates in the normal mammary
samples. All mammary lesion samples showed lower expression
levels that the normal samples (Figure 5).
The Student’s t-test (two-tailed) demonstrated that the disease-
free mammary samples showed ERBB2 RNA expression levels
that were significantly higher than the benign (p = 3.4E-09),
malignant (p = 6.4E-12) and metastatic (p = 4.07E-12) samples.
Also, the benign samples showed significantly higher values of
ERBB2 RNA expression (p = 0.002) compared with the malignant
samples (Figure 5).
For comparison of the ERBB2 RNA levels, we also determined
the lesion/normal ratio using the mean values for each individual
sample and for the groups of samples (Figure 5). The samples that
showed a lesion/normal ratio .0.5 were considered to not be
underexpressed (Figure 5: sample MeL5).
We would like to highlight that the MaL16-MaL17 and
MaL20-MaL21 samples, corresponding to the first occurrence
and recurrence of the mammary lesion, respectively, showed
similar expression values: MaL16 (mean 6 SD: 2.000060.0173)/
MaL17 (mean 6 SD: 1.606760.2193) and MaL20 (mean 6 SD:
1.590060.3117)/MaL21 (mean6 SD: 1.873360.0577) (Figure 5).
Additionally, when comparing the primary lesions with the
corresponding lymph node lesion (MaL22-MeL4), the RNA
expression levels were similar but higher in the metastatic samples.
We also observed that different metastatic tissues (MeL5-8) from
the same primary malignant lesion (MaL14) showed different
expression levels.
Statistical correlation tests between the
clinicopathological features of the mammary lesions, the
detected sequence variants, and the IHC and RT-qPCR
results
A two-tailed Pearson correlation analysis (confirmed by Spear-
man’s test) was performed, considering all of the clinicopatholog-
ical features of the mammary lesions, the detected sequence
variants, and the mRNA and erbB-2 protein expression levels
attained in the present work (SPSS version 17.0; significant p-
values .0.05). The significant correlation are summarize in
Table 2 (Table S6 and Table S7).
The correlation test between the sequence variants and the
CML clinicopathological features revealed a positive correlation
between primary lesion size and high frequency of 2 SVs detected
in the normal and CML samples (g.271T.G and g.280G.A). In
addition, the SV g.335C.T showed a positive correlation with
vascular infiltration, and g.1914G.C showed a negative correla-
tion with the histological classification (Table 2). Regarding the
immunohistochemical results, some significant correlations were
found. Negative correlations between the CB11/int results and the
histological classification and between the CBE356/ext results and
nuclear/cellular pleomorphism were observed (Table 2). A
positive correlation was observed between the IHC results
obtained with the two antibodies (Table 2). Concerning the IHC
and RNA expression results, a positive correlation was shown
between the IHC results with the CB11/int antibody and the
Figure 5. ERBB2 RNA expression in mammary lesions samples. The graphic with two independent Y axis illustrates the measure of RNA
expression output as concentration_ratio_x_100 mean values (left Y axis with red values) with standard deviation values (black lines in red columns)
and also the analysis of lesion/normal mean values ratio (right Y axis with blue values) for each sample and groups of samples.
doi:10.1371/journal.pone.0083673.g005
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mRNA expression levels. Finally, a positive correlation was
discovered between RNA underexpression levels and a worse
clinical outcome (Table 2).
Discussion
Cat mammary lesions ERBB2 genomic sequence variant
analysis
In the present work, we performed an extensive ERBB2 gene
sequence variant analysis in cat mammary lesions, including
neoplastic and non-neoplastic lesions, and a group of normal
genomic DNA samples as a control group. Our study focused on
the cat ERBB2 gene from exon 10 to 15, which encodes part of the
extracellular domain of the erbB-2 protein. The complete cat
ERBB2 genomic wild-type sequence from exon 10 to 15 (2173 bp)
was obtained for the first time in the present work and was
submitted to GenBank (accession number JQ284376). Thirty de
novo SVs were identified in the cat ERBB2_10-15 genomic
sequence, 6 of which were only observed in the normal samples
and 9 of which were only detected in the CML samples. A higher
number and frequency of SVs were demonstrated for the CML
genomes, and some specific DNA variants were detected in
different types of mammary lesions (Table S3).
Seven SVs were localised in exonic regions, 5 of which were
revealed to be non-synonymous SVs (nsSVs). Four nsSVs were
only detected in the CMLs (JQ284376: g.229T.A, g.2037G.C,
g.2041A.C, g.2065T.C). The main outcomes concerning SVs
detected in the present study are review in table 3. The 10 SVs
detected in normal and CML samples, that showed HWE allelic
deviation, may be considered as normal germline variants and
could be involved in disease susceptibility (Table S3). A basic single
allelic model of association demonstrated that five variant alleles,
which were only detected in CMLs, showed significant values of
association with mammary lesion samples group (JQ284376:
g.355G.A, g.1914G.C, g.2037G.C, g.2041A.C, and
g.2065T.C). The determination of the haplotype frequency for
cat ERBB2 using the linkage disequilibrium test uncovered a
divergent genotypic haplotype characterisation (nine different
frequent haplotypes) between the normal samples and mammary
lesion samples (table 1).
With this approach, we intended to contribute new data
regarding the role of the ERBB2 gene in the cat mammary tumour
system. As far as we know, this is the first attempt to detect and
analyse cat ERBB2 sequence variants in the genomic fragment
from exon 10 to 15 (2173 bp) in normal samples and CML
samples. There is only one previous work analysing partial
sequences of the cat ERBB2 gene between exon 17 and 20 (548 bp
in length) that demonstrated the presence of two specific SVs and
two specific haplotypes in CML samples [44].
The present work demonstrated that the majority of the cat
ERBB2_10-15 SVs detected were already present in early pre-
malignant lesions and that the metastatic lesions showed a lower
frequency of heterozygosity. Also, considering only the CML
samples, the percentage of the minor allele was higher for the
benign samples than in the primary malignant and metastatic
samples, demonstrating that some variants were lost during
tumour evolution (Table 3 and Table S3). These conclusions
corroborated with the previous results, demonstrated for human
breast cancer, concerning the idea that progression to an invasive
carcinoma is associated with only a few additional changes [46]
and that the loss of heterozygosity on a specific genetic variant is
associated with genetically advanced tumours [11,47,48]. There-
fore, our results reiterate that the allelic heterogeneity is found in
early human breast lesions and are in agreement with those of
various authors who consider the human ERBB2 proto-oncogene
to be a natural target for sequence variant analysis [49], as the
encoded transmembrane tyrosine kinase receptor protein is highly
recognised to have an important role in human breast cancer
prognosis [49–51]. Concerning SV studies in human breast
cancer, the rs1801200 ERBB2 polymorphism (detected in exon
17), which corresponds to the Ile655Val mutation in human erbB-
2, was extensively investigated as a risk factor for breast cancer by
several authors [49,52]. However, a recent review of case–control
studies failed to find any association between the variant allele and
breast cancer [53]. This is in agreement with the idea that in a
complex system such as the mammary gland cell, a single genetic
variant is unlikely to have a strong effect on the clinical phenotype
[54]. Some evidence for gene-gene interactions among the
sequence variants (SVs-SVs interaction) has been previously
demonstrated, supporting the fact that the mechanisms by which
single nucleotide polymorphisms influence breast cancer risk is
incremental [49,55–58]. Also, it is possible that single genetic
variants previously detected, are in linkage disequilibrium with a
truly causal allele that remains to be identified [31]. In fact, in the
present work 3 of the SVs detected (including 2 nsSVs), were
observed in the frequent CML haplotypes, always in the presence
of other SVs, that might indicate resistance or susceptibility to
breast cancer development.
Probable structural damaging effects, homology
modelling and molecular dynamics studies of wild-type
and variant cat erbB-2 protein
To our knowledge, this is the first time that a cat erbB-2
homology model has been published (Figure 2) and that software
tests have been performed to investigate the possible effects of
amino acid changes on the 3D structure and function of cat erbB-2
(table 3).
All data indicate that the g.226G.A nsSV, only detected in the
normal samples, and corresponding to the Arg46Lys benign
change, can be considered a normal germline variant.
Comparing the human and cat erbB-2 wild-type models, we
demonstrated that the CR1/L2 interaction region showed a
conserved network of H-bonds and charged residues. The Val47 is
localised in the L2 extracellular domain in the region of the CR1/
L2 domain interaction network. In SA simulations, the Val47Glu
change, promoted a considerable rearrangement in the hydrogen
bond network. The two new H-bonds formed (Figure 2b) are able
to further stabilise the CR1/L2 interaction and by exposing the
CR1 domain to dimerisation, can help to maintain an active ready
form of the cat erbB-2 protein that, as previously demonstrated for
human erbB-2 favours the cancer process by promoting signal
transduction [59,60].
The two new H-bonds formed (Figure 2b) are able to further
stabilise the CR1/L2 interaction and by exposing the CR1
domain to dimerisation can help to maintain an active ready form
of the cat erbB-2 protein that, as previously demonstrated for
human erbB-2, favours the cancer process by promoting signal
transduction [59,60].
In addition, the Val47Glu change, classified as possibly
damaging to the protein structure, and the corresponding
g.229T.A nsSV that was only observed in the metastatic samples
should be considered for further analysis, specifically concerning
the metastatic process of cat mammary gland carcinomas.
The last 3 amino acid variants (Ala205Pro, His206Pro, and
Val214Ala) were detected in the CR2 domain. Our straightfor-
ward analysis showed that the His206Pro and Val214Ala amino
acid changes altered the side chain polarity and volume, which
could modify the accessible surface propensity of the CR2 domain
The Cat as Model for erbB-2-Negative HBC
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and produce the closest contact with other nearby side chains.
Also, the 3 nsSVs, corresponding to these 3 mutations, were
identified in the same CML haplotype (haplotype 15; Table 1 and
2). We hypothesise that amino acid variant interactions could have
incremental effects on the cat erbB-2 protein structure, function,
and therapeutics, as it is known that the CR2 domain plays an
important role in human breast cancer treatment. In fact,
trastuzumab (HerceptinH) is a monoclonal therapeutic antibody
against breast cancer that targets erbB-2 by interacting with the
CR2 domain, thus preventing erbB-2 dimerisation (Figure 3a).
In a previous work, Rajasekara and collaborators (2008) studied
the effect of nsSVs on the 3D structure of the human erbB-2
protein and its potential use in breast cancer therapy [61].
Moreover, they proposed that Herceptin is the best drug for erbB-
2 mutants compared to the native erbB-2 target.
Rajasekara and collaborators (2008) proved that not only do AA
changes occur in the CR2 domain, but also changes in the L2
domain could promote conformational alterations in the CR2
domain and consequently change the affinity of the protein to
trastuzumab (HerceptinH) [61]. This idea reveals a potential
consequence for the Val47Glu AA mutation in the L2 domain in
cat erbB-2_10-15 detected in the present work, which was
classified as being probably damaging to the 3D erbB-2 structure.
Finally, by comparative analysis, we observed that the 3 AA
changes detected in the CR2 domain of cat erbB-2 (Ala205Pro,
His206Pro and Val214Ala) do not interact directly with
trastuzumab. However, in the human erbB-2 model, residues
566, 567 and 575, which correspond to the Ala205Pro, His206Pro
and Val214Ala cat erbB-2 variants, respectively, are localised
closer to the major key residues (Glu558, Asp560 and Lys569) [61]
and between the loops that mediate the erbB-2 protein-Herceptin
interaction (Loop557-561, Loop570-573 and Loop593-603) [55].
This proximity indicates a potential effect on the affinity of the cat
erbB-2 variant protein for trastuzumab.
In conclusion, our results concerning sequence variation
detection in cat mammary non-neoplastic and neoplastic lesions,
are an important contribution to genomic DNA characterisation
in cancer, corroborating the idea fomented by Tao and
collaborators (2009) for human cancers that large epidemiological
studies of predisposed gene polymorphisms can provide new
insights into the in vivo relationships between genes of interest and
cancer risk [49]. In addition to the individual investigation detailed
in the present work, the simultaneous occurrence of nsSVs in some
haplotypes, that were only detected in cat mammary lesions, could
indicate a SV-SV interaction that impacts the effects of the amino
acid changes in the 3D structure of the cat erbB-2 protein, which
may indicate resistance or susceptibility to breast cancer develop-
ment and therapy. We believe that further efforts should be made
in order to extend the studies of these cat erbB-2 mutations in cat
mammary lesions and to analyse their importance in cat
mammary tumour evolution.
Table 3. Resume of the main outcomes concerning genomic sequence variants (SVs) detected.
Genomic sequence variants
g.226G.A g.229T.A g.355G.A g.1914G.C g.2037G.C g.2041A.C g.2065T.C
Minor allele percentage (%)
Normal 7.69
BeL 37.50 25.00 37.50 25.00
MaL 18.75 25.00 16.67 33.33 25.00
MeL 16.67 33.33 16.67 83.33 33.33
Heterozygosis percentage (%)
Normal 15.38
BeL 75.00 50.00 25.00 50.00
MaL 37.50 50.00 33.33 33.33 50.00
MeL 33.33 00.00 33.33 33.33 66.67
Allelic Association tests
Normal vs. CMLs No No Yes Yes Yes Yes Yes
Genotypic Association tests
Normal vs. CMLs No No No Yes Yes Yes Yes
Clinicopathological Correlation
CMLs No No Yes Yes No No No
SVs and AA changes analysis in Total Group of Samples
SVs Position Exon 11 Exon 11 Intron 12 Intron 14 Exon 15 Exon 15 Exon 15
Haplotypes with SVs 7 17 No 15; 16; 18 15; 18 11; 15; 17 15; 16; 17; 18; 19
Percentage of SV in
Haplotypes (%)
8 0.5 ,0.05 0.15 0.1 0.35 0.25
AA changes Arg46Lys Val47Glu NA NA Ala205Pro His206Pro Val214Ala
Probably effect in protein Benign Damage NA NA Benign Damage Damage
Sequence variants key marks reveal by experimental, statistic and in silico analysis. A detailed integrative analysis of nsSVs and their corresponding amino acid changes.
The haplotypes corresponds to the frequent haplotypes detected in total samples (frequency .5%). SVs with probably damage effect in protein are in bold text. (%)
Percentage. (NA) not applicable. (No) not observed.
doi:10.1371/journal.pone.0083673.t003
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Quantification of the erbB-2 protein by
immunohistochemistry and ERBB2 RNA by RT-qPCR
The erbB-2 expression levels in the normal and CML samples
were detected by IHC using two antibodies against different
regions of the erbB-2 protein: CB11 antibody, which has affinity
for the intracellular region (CB11/int); and CBE356 antibody
which has affinity for the extracellular region (CBE356/ext). The
IHC membrane labelling scores revealed some disparity between
the results for the two antibodies and consistently demonstrated
superior intracellular expression levels. In the normal samples, we
observed a surprisingly higher percentage of moderate to complete
erbB-2 membrane labelling (erbB-2 positive) for both antibodies
(91.7% CB11/int; 66.7% CBE356/ext). Regarding the cat
mammary lesions, the benign lesions generally showed a higher
percentage of erbB-2 positivity (100% CB11/int; 75% CBE356/
ext), but their values were similar to those of the normal samples.
However, the primary malignant (erbB-2 positive: 47.6% CB11/
int vs. 41.17% CBE356/ext) and metastatic lesions (erbB-2
positive: 41.66% CB11/int vs. 8.33% CBE356/ext) demonstrated
a higher percentage of erbB-2 IHC negative samples (Figure 4). In
the different cases tested (normal and mammary lesions) we didn’t
found any ERBB2 gene amplification.
In several studies of cat mammary tumours, alterations of the
ERBB2 proto-oncogene have been described, mostly at the protein
level [4,38,41,42,62]. With respect to our IHC erbB-2 analysis, the
results for the normal samples are in accordance with the work of
Burrai and collaborators (2010), which also found erbB-2 protein
expression in normal cat mammary epithelium with strong,
complete membrane staining [4]. These findings are contrary to
those of other studies that reported no immunoreactivity or a faint,
barely perceptible signal in part of the cell membrane in normal
cat mammary ducts and acini [41–43,63], and they are also
contrary to what has been mainly observed in humans [64].
However, reports of erbB-2 expression in normal human tissues
have varied between studies, but it is definite that because of its
role in normal cells, the erbB-2 protein is expressed widely in
epithelial cells, particularly those of the secretory epithelia, such as
the mammary gland [65]. Our data reinforce the idea suggested
by Burrai and collaborators (2010) that the erbB-2 protein could
be present at higher levels in the normal cat mammary gland
compared to the normal human mammary gland [4].
As far as we know, there is only one recent work that also
applied antibodies against the intracellular (4B5, A0485 and
CB11) and extracellular (TAB250, SP3) regions of the erbB-2
protein, in normal cat glands and cat mammary lesions. However
these authors demonstrated that neither TAB250 nor SP3
antibodies showed reactivity with the extracellular regions of the
cat erbB-2 protein [62]. The majority of works, with respect to
erbB-2 IHC analysis in cat mammary tissues, uses antibodies with
affinity for the intracellular region of the erbB-2 protein, which
include: A0485 [4,38,43]; CB11 [41]; A0485 and CB11 [42]; and,
4B5, A0485 and CB11 [62,63].
Despite the antibodies used, different authors found dissimilar
ranges of erbB-2 protein overexpression (erbB-2 positive IHC) in
cat mammary lesions: 76.7–90%, 59.6%, and 39% (2005); 40%
(2007); 27% (2010); 5.5–10% (2011), and 20–33% (2013)
[4,38,41–43,62,63]. A deeper analysis of the percentage of cat
mammary lesions with erbB-2 overexpression obtained in previous
works and in the present manuscript demonstrates that with more
recent techniques, it appears likely that a low percentage of cat
mammary carcinomas overexpress the erbB-2 protein. Thus, it is
clear that technical factors can affect the immunohistochemical
assessment of erbB-2 expression in cat mammary gland samples
[63]. Concordantly, several authors reported that despite the fact
that IHC is currently used for human breast cancer erbB-2 protein
categorisation, the application of different, common, commercially
available erbB-2 antibodies produces variability in the IHC results
[65–69]. This fact also sustains the recent suggestion that
quantification of ERBB2 mRNA transcripts by RT-qPCR can
be used to determine prognoses in breast cancer as an additional
molecular test to the erbB-2 IHC test [34]. In human breast
cancer, several works refer to ERBB2 mRNA overexpression in a
low percentage of samples [39,70], and some recent works have
also observed low levels of ERBB2 mRNA, suggesting the
occurrence of ERBB2 mRNA underexpression in HBC [39,40].
In the single previous publication concerning ERBB2 RNA
expression levels in cat mammary tumours, the authors reported
that 55% of the neoplastic lesions showed increased RNA
expression [38], but no information was provided regarding the
remaining 45%, which suggests that the rest of the samples showed
similar or lower RNA expression than the control (RNA pool with
3 normal samples). As discussed for the IHC results, this
heterogeneity could be explained by differences in technique, as
dissimilar ‘‘cut-offs’’ have been utilised by different authors and
many did not quantify the ERBB2 mRNA expression in normal
tissues compared with cancerous tissues [33].
In fact, in the present work, the ERBB2 RNA expression levels
in the cat mammary samples were evaluated by RT-qPCR,
applying primers and probes that detected sequences responsible
for the translation of the intracellular region of the erbB-2 protein.
The results were surprising, as all of the normal mammary samples
(n = 5) demonstrated higher expression values than all of the cat
mammary lesion samples, which generally corroborated with our
IHC results. Also, as all of the benign and primary malignant
lesions and 4/5 of the metastatic samples demonstrated a
statistically significant ERBB2 RNA underexpression in relation
to the group of normal mammary samples (Figure 3). When
comparing the different groups of lesion samples, the primary
malignant lesions showed significantly lower expression levels of
ERBB2 mRNA than the benign lesions.
In the present research, we found a positive correlation between
the ERBB2 RNA and protein expression levels in the intracellular
region (CB11/int antibody), but a lack of correlation between the
ERBB2 RNA and protein expression levels in the extracellular
region (erbB-2 CBE356/ext antibody). These results are in
agreement with the fact that ERBB2 RT-qPCR was performed
with primers and probes specific for the RNA sequence that
translates part of the intracellular region. This suggests that
different transcripts could be involved in the different expression
patterns obtained with the two antibodies used, as previously
reported in human breast cancers, which also presented a
statistically significant correlation between ERBB2 mRNA RT-
qPCR and protein IHC expression levels [71,72]. In fact, p95, an
aberrant form of erbB-2, is not detected by antibodies that target
the external domain of erbB-2 because the extracellular domain is
missing in this protein [73,74]. Interestingly, in this work, we
found lower levels of CBE356/ext labelling in all tissue sample
types, including the normal samples, suggesting the presence of
this erbB-2 isoform. Moreover, another mechanism of ERBB2
gene expression regulation could be involved, such as specific
promoter regulation [75], defective RNAs, and mutations in
ERBB2 [76]. Camp and collaborators (2003) speculated that
tumours might overexpress another growth factor receptor that
promotes tumour aggression via a ligand-dependent or -indepen-
dent mechanism [39,76,77]. Moreover, comparative analysis
showed enrichment in alternative events in ERBB2 over-express-
ing cells, indicating regulation of alternative splicing mediated by
the oncogene [78]. Some authors have illustrated that erbB-2 IHC
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tests generally reveal a correlation between an erbB-2 positive
status and an aggressive phenotype [79], but other authors have
proposed that normal levels of the erbB-2 protein could be
associated with a similar aggressive phenotype [77,80]. Addition-
ally, even patients with low erbB-2 expression levels and worse
outcome may confer important therapeutic potential being
however ineligible for anti-HER2 therapy [80,81]. This point of
view is also in agreement with our results that indicated the
presence of some association between low ERBB2 RNA and erbB-
2 protein expression levels with a worse cat mammary lesion
prognosis.
Conclusions
We believe that this work reports the most complete character-
isation of the cat ERBB2 gene in normal samples and cat
mammary tumour lesions to date. The present study is the first
report to detect amino acid variants in the extracellular region of
the cat erbB-2 protein and their potential effects on the interaction
of the protein with the therapeutic antibody trastuzumab. The
results of our ERBB2 gene expression analysis suggest the presence
of ERBB2 gene post-transcriptional regulation and the occurrence
of proteins with truncations and single point mutations in cat
mammary neoplastic lesions. We should emphasise that our IHC
and RT-qPCR results assigned the analysed cat mammary
primary malignant lesions to a subtype of cat mammary
carcinomas that are characterised by ERBB2 RNA and erbB-2
protein underexpression. Here, we demonstrate the prognostic
value of the ERBB2 gene in cat mammary tumours, identifying
this gene into a potential therapeutic target, similar to the results
demonstrated for HBC. Additionally, the recurrent occurrence of
low erbB-2 expression levels in cat mammary tumours suggests
that cat mammary neoplasias could be a valuable model for erbB-
2 negative human breast cancer.
Methods
Normal and mammary lesion samples
All the owners gave permission to collect the samples of their
cats acknowledging that they may be used for research purposes.
After owners consent, all samples were collected in accordance
with EU Directive 2010/63/EU and approved by the Ethics
Committee of Porto University (approval number EC/12-04/
POCI/CVT/62940/2004). The samples used in the presented
work have been describe in previous publications [44,82]. All cat
mammary lesion samples were histologically classified according to
the diagnostic criteria proposed by the World Health Organiza-
tion (WHO) classification of mammary tumours of the dog and cat
[83]. When available, clinical characteristics, including age at
diagnosis, previous diseases and number of lesions, were obtained
from medical records over a period of 2 years [84]. A mammary
lesions histological and clinical grading evaluation (including
prognostic factors) was execute accordingly with Gimenez and
collaborators [85] and Misdorp and collaborators [6].
For the sequence variant analysis, we used 14 blood samples
and 15 fresh mammary lesion samples. In addition, we used 4 cat
mammary carcinoma formalin-fixed paraffin-embedded tissues
(FFPET) from an archive. The fresh mammary samples were
recovered during mastectomy and immediately frozen in order to
preserve the DNA. Ten normal samples (blood) were obtained
from animals that also bore a mammary gland lesion.
To measure the ERBB2 RNA expression levels, we collected 5
normal mammary glands and 23 fresh mammary lesion samples.
These samples were frozen (280uC) in a RNA stabilisation
solution (RNA Later Tissue Collection, Ambion). The normal
mammary gland samples were obtained from five different queens
at necropsy with no evidence of pathological mammary condi-
tions. The mammary lesion samples were collected during
mastectomy.
The immunohistochemical (IHC) erbB-2 protein quantification
analyses of the mammary lesion samples were performed on the
samples used for the quantification of RNA expression (except 1
malignant lesion and 1 metastatic sample were unavailable for this
procedure). Additionally, 7 metastatic lesions and the 4 FFPET
samples utilised in the genomic SV study were also used in the
IHC analyses. A total of 21 primary and 12 metastatic CML
samples were submitted to IHC. Additionally, 12 normal
mammary tissues were analysed (4 normal mammary samples
and 8 residual normal mammary glands peripheral to the
mammary lesions).
Extraction of genomic DNA and total RNA
The nucleic acids from the FFPET (genomic DNA - gDNA) and
fresh/frozen samples (gDNA and RNA) were extracted and the
quality and concentration were evaluated as described previously
[82,86].
Analysis of the cat ERBB2_10/15 fragment in normal
samples
The four primers used were designed based on two cat
sequences from the National Center for Biotechnology Informa-
tion (NCBI) genome browser (cat ERBB2 mRNA, GenBan-
k:AY702651.1; cat ERBB2 DNA, GenBank:AY685128) and the
human sequence (human ERBB2 DNA, GenBank:NG_007503).
The primer sequences were as follows: E10 sense, 59-GGACC-
CAGCCTCCAACACTG-39; E12 sense, 59-GGACGAGTGC-
GGTAAGACAG-39; E14 antisense, 59-AGGTCACTGAGCCA-
TTCTGG-39 and E15 antisense, 59-GAGTGGGTGCAGTT-
GATGGG-39. Polymerase chain reaction (PCR) experiments and
PCR products evaluations were performed according to Santos
and collaborators [44]. In order to amplify and sequence the
ERBB2_10-15 gene fragment, the primer set E10/E15 was applied
using gDNA obtained from two blood samples from two cats with
no history of mammary disease. The PCR fragments were excised
from the agarose gel, purified (Geneclean II kit; BioGene), and
cloned into the pCR 2.1-TOPOH vector (TOPO TA cloningH kit;
Invitrogen/Life Technologies). The plasmid DNA was extracted
(Quickgene DNA plasmid kit; Fujifilm/Life Sciences), and four
positive clones were selected for sequencing. The sequences were
evaluated with Vector NTI software (Invitrogen/Life Technolo-
gies). The sequences were determined in both directions using the
DNA Sequencing Kit (ABI Prism).
ERBB2_10-15 sequence variants detection in normal and
mammary lesion samples
To perform gDNA sequence variant detection in normal and
CML samples, gDNA fragments were amplified with two sets of
primers: E10/E14 (from exon 10 to 14) and E12/E15 (from exon
12 to 15). The positive PCR reaction products were purified, and
sequencing was performed in both directions. The sequences were
edited directly with the chromatograms in the ContigExpress
Vector NTI module (Invitrogen/Life Technologies), and a final
consensus sequence was established for each sample.
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ERBB2_10-15 coding sequence prediction and in silico
analysis
A search for human and cat ERBB2 exon structure was
performed using the NCBI, Ensembl and GeneCards browser
databases. A comparative analysis allowed for the recognition of
the boundaries of exon 10 to 15 in the genomic ERBB2_10-15
wild-type (wt) sequence. We constructed a variant genomic
sequence (ERBB2_10-15_SV) in silico that comprised all of the
detected variant alleles (Vector NTI 10.3.0 software; Invitrogen/
Life Technologies). Coding region sequences (CDSs) and protein
sequences were determined based on the wild-type and variant
DNA sequences. This intricate analysis involved the validation of
the gDNA, DNA coding region and protein sequences obtained
from the genome and protein databases (Ensembl, UCSC
Genome Browser, UniProtKB/TrEMBL and NCBI) by align-
ment.
Determination of Hardy-Weinberg equilibrium, genotype
association and genomic haplotype
All statistical tests described in this subsection were performed
with SVS7 software (SNP and Variation SuiteTM 7; Golden
Helix). Chi-square test results were considered to have significant
values at 5% (p-value ,0.05). Changes in the HWE were
evaluated and verified by chi-square tests for all cat ERBB2 SVs
detected in our experiment. Basic single allelic and genotypic
models of association (chi-square test) were used to evaluate the
allelic and genotypic frequency differences between the normal
and mammary lesion samples. SVs with a p-value ,0.05 were
considered to be associated with cat mammary lesions.
The haplotype frequencies were estimated for the three groups
of samples: normal samples, mammary lesion samples and total
samples. The haplotype determination was based on the pairwise
measure of the linkage disequilibrium between all of the SVs
detected (D9 statistic) [87]. The chi-square test was used to test
associations between the SVs in order to identify haplotypes.
Computational analysis, homology modelling and
molecular dynamics studies for the cat erbB-2 protein
PolyPhen and PolyPhen-2 software was used to identify
homologues via a BLAST search of the nrdb database (Natural
Resources Database) and a BLASTP query sequence against the
protein structure database (PDB: Protein Data Bank). The
resulting multiple alignment was used to compute the absolute
PSIC (Position-Specific Independent Counts) value of the differ-
ence between the profile scores of both allelic variants in the
polymorphic position. PolyPhen uses empirically-derived rules to
predict that an nsSV is probably damaging, possibly damaging, or
benign to protein function or structure. The output shows several
characterisations of the substitution site, such as a hydrophobicity
change and changes in the residue side chain volume (measured in
A˚3). In addition, the automatic bioinformatics tools of PolyPhen-2
predict whether an amino acid substitution affects the protein
function or stability based on sequence homology and the physical
properties of amino acids mapped in a substitution site of the
three-dimensional (3D) structure of a known protein. The output
includes a probability score that classifies the mutation as possibly
damaging (score ,0.15), probably damaging (score . 0.85) or
benign (score 0.15–0.85).
In order to complete the homology modelling and molecular
dynamics studies, a cat erbB-2 wild-type homology model was
built using the SWISS-MODEL online homology modelling
server [88]. The complete human erbB-2 structure was kindly
supplied by Dr. Pe´ter Bagossi [89] and was used as a template file
for the SWISS-MODEL server. From the prepared wt cat erbB-2
model, different homology models of the 5 detected variants were
established by incorporating the respective mutation. Using the
Protein Preparation Wizard protocol available in the Maestro
software program [90], the extracellular domains of the homology
models of cat ERBB2 wt and the 5 variants were prepared, with
hydrogens added and water molecules removed. The wt and
variant 3D models were aligned using Pymol software, and a
preliminary comparative analysis was performed.
Before applying the simulated annealing (SA) protocol,
Desmond software (D.E. Shaw Research, New York, NY) was
used to add water molecules around the proteins and sodium ions
to neutralise the negative charges. All structures were then
subjected to SA. The stages used in this study were standard for
SA simulations using Desmond software. The simulation time was
1.2 ns with a recording interval of 1.2 ps. The system was heated
from 0 to 400 K and then stabilised at 300 K and 1 atm using the
Berendsen thermostat in six separate stages. The last frame of each
simulation was used to structurally analyse the variants. Structural
alignments and image preparations were obtained using Pymol
software.
Protein quantification by immunohistochemistry
Tissues were fixed in 10% buffered formalin (#48 hours), and
embedded in paraffin. Three consecutive, 3 mm thick sections
were cut; one was stained with haematoxylin and eosin for
histopathologic diagnosis, and the others were used for the IHC
study. The haematoxylin/eosin-stained sections were indepen-
dently examined by two pathologists.
For the IHC study, sections were deparaffinised and hydrated,
and antigen retrieval was performed in a pressure cooker in
10 mmol/L sodium citrate buffer (pH 6.0) for 2 min. The slides
were cooled for 10 min at room temperature and rinsed twice in
triphosphate buffered saline (TBS) for 5 min. After blocking
endogenous peroxidase with 3% hydrogen peroxide in methanol
for 10 min, the sections were incubated with the following two
monoclonal antibodies at a dilution of 1:40 mouse anti-human
erbB-2 oncoprotein CB11, which is specific for the internal
domain (CB11/int), and mouse anti-human erbB-2 oncoprotein
CBE356, which is specific for the external domain (CBE356/ext)
(Novocastra, Newcastle, UK). The sections were subjected to
immunohistochemical staining for 90 min and visualised with the
NovolinkTM Max-Polymer detection system (Novocastra). The
sections were rinsed with TBS between each step of the procedure.
Colour was developed for up to 7 min at room temperature with a
freshly prepared solution of 3,39-diamino-benzidine, and the
sections were then lightly counterstained with haematoxylin,
dehydrated and mounted. ErbB-2 positive human breast carcino-
ma samples were used as positive controls, while the primary
antibody was replaced by isotype-specific IgG in negative controls.
The immunoreactivity of erbB-2 was assessed according to the
Hercep-Test scoring criteria, described in the American Society of
Clinical Oncology (ASCO) guidelines [45]. A minimum of 1,000
cells were counted in at least 10 random high-power (4006) fields.
In accord with the strength of immunostaining, the samples were
scored as: 0, no labelling; + (or 1+), weak and incomplete
membrane labelling; ++ (or 2+), weak to moderate complete
membrane labelling of at least 10% of the tumour cells; and +++
(or 3+), strong and complete membrane labelling of at least 10% of
the tumour cells. Samples showing areas with different scores (0/+,
+/++ or ++/+++), were evaluated in agreement with erbB-2 scores
in 10% of tumour cells in the total area analysed. Cat mammary
lesions scored as 0 or + were considered erbB-2 negative, whereas
The Cat as Model for erbB-2-Negative HBC
PLOS ONE | www.plosone.org 13 December 2013 | Volume 8 | Issue 12 | e83673
those scored as ++ or +++ were considered erbB-2 positive for
immunostaining.
SDS-PAGE and Western Immunoblotting
Protein was extracted from frozen samples at 280uC preserved
in RNAlater (Ambion, Invitrogen Life Technologies), of 2 cat
mammary lesions and 2 normal mammary glands. Protein
extraction was performed with Qproteome Mammalian Protein
Prep Kit (Qiagen) in accordance with manufacturer’s recommen-
dation. After extraction the protein were stored at 220uC until
needed. For electrophoresis, before being loaded, samples were
prepared by mixing the protein extract (3 ml) with 5xSDS loading
buffer (12 ml) and denaturing at 95uC for 5 min. The proteins
were loaded on a NuPAGEH Novex 4–12% Bis-Tris Mini Gel
(Invitrogen Life Technologies) and subjected electrophoresis with
MOPS running buffer at a constant voltage of 200 V for 50 min
(XCell SureLockTM mini-cell electrophoresis system; Life technol-
ogies). BlueStar Plus Prestained protein marker (Nippon Genetics
Europe) was included in the gel. The proteins were stained with
AdvanStain Scarlet (Advansta) and digitized with an imager
system (UV).
For western immunoblots, electrophoresed proteins were
transferred to PVDF membranes in the iBlotH gel transfer device
(iBlotH gel transfer stacks; Invitrogen Life technologies), and
blocked with 5% skim milk in PBS-T (phosphate buffered saline
with 0.05% Tween 20) for 1 hour. The antibodies were prepared
in PBS-T with 2% skim milk. Half of the membrane was then
incubated with the anti-human erbB-2 oncoprotein CB11
antibody at 1: 300 dilution. The other half of the membrane
was incubated with the anti-human erbB-2 oncoprotein CBE356
antibody at 1:80 dilution (Novocastra, Newcastle, UK) for 1 h or
overnight at 4uC with agitation. The membranes were then
washed with PBS-T with 1% skim milk, and incubated for 1 h
with, HRP conjugate goat-anti-mouse secondary antibody (Ad-
vansta) in PBS-T plus 2% skim milk. The results were visualized
with chemiluminescent HRP substrate (WesternBrightTM ECL kit;
Advansta).
ERBB2 DNA copy number absolute quantification
For ERBB2 absolute quantification we used the standard curve
method. The PCR primers for ERBB2 analysis were: 59-
GAGTGCGGTAAGACAGGGAG-39 and 59-AGTCTGCA-
CAAGTCCGAGAT-39. A 2-fold serial dilution series of the
plasmid DNA with the ERBB2 insert already referenced in this
section (cf. ‘‘Analysis of the cat ERBB2_10/15 fragment in normal
samples’’), ranging from 3.126107 to 1.956106 copies, was used to
construct the standard curve (5 points series dilutions) (standard
curve in supplementary material; Figure S5). The concentration of
the plasmid with the insert was measured using the NanoDrop
ND-1000 (NanoDrop Technologies) equipment and the corre-
sponding plasmid copy number was calculated
using the following equation: DNA (copy num-
ber) = [6.02361023 (copy number/mol) 6 DNA amount (g)]/
[DNA length (bp)6660 (g/mol/bp)], where Avogadro number is
6.02361023 (copy number)/1mol and the average molecular
weight of a double-stranded DNA molecule is 660 g/mol/bp. In
the respective formula the recombinant plasmid DNA length is
4650 bp (pCR 2.1-TOPO vector 3900 bp and the insert 750 bp).
CT values in each dilution were measured using real-time qPCR
to generate the standard curve for ERBB2. Briefly, the standard
curve includes a plot of the CT values versus the log concentration
of the ERBB2 standard. For normal and tumour lesions cat
genomic DNA, the unknown total DNA sample, was obtained by
interpolating its CT value against the standard curve. We analysed
10 normal cat mammary samples and 12 cat mammary lesions
(supplementary material, Figure S5). In the PCR reaction we used
20 ng of genomic DNA. The reactions were performed with the
MeltDoctor HRM Master Mix, which use the SYTO9 dye
(Applied Biosystems, Invitrogen Life Technologies) following the
recommendations of the manufacture. This experiment was
carried out in the StepOne real-time PCR system (Applied
Biosystems, Invitrogen Life Technologies), where the samples were
subjected to an initial denaturation at 95uC (10 min), and then to
40 cycles at 95uC 15 sec followed by 61uC 1 min. Afterwards a
melt curve was performed in order to evaluate the primer
specificity. All reactions were performed in triplicate, and negative
controls (without DNA) were also run.
The StepOne software (version 2.2.2, Life Technologies
Applied Biosystems) was used to generate the standard curve
and for data analysis. Only standard curves with the following
parameters were considered to be typically acceptable: R2.0.99
and slopes between 23.1 and 23.6 giving reaction efficiencies
between 90 and 110%.
The absolute quantification of ERBB2 allowed determining the
copy number of this sequence in cat mammary normal and lesions
genomes that corresponds to 20 ng which, in turn, comprises 5714
haploid genomes. The mass of Felis catus haploid genome was
obtained in Genome Size database (http://www.genomesize.
com/) as being 3.5 pg (3.561023 ng).
RNA expression analysis by quantitative real-time
polymerase chain reaction (RT-qPCR)
Primers were designed and probes were selected against
conserved cat and human cDNA sequences corresponding to the
ERBB2 sequence that encodes the internal region of the cat erbB-2
protein. Primers (F, 59-CTTTTGGGGCCAAACCTTAT-39 and
R, 59-CTAGTGGGACGCGGACAT-39) were designed using
Roche LightCycler Probe Design Software (version 2.0). The
concentration of the working solution was 20 mM for all oligomers.
The hybridisation probe was selected from the Human Universal
Probe Library from Roche Applied Science (UPL58). The GAPDH
gene was used as a housekeeping gene. The qRT-PCR analysis was
performed according to the methodology previously described by
Baptista and collaborators [85].
The Student’s t-test (two-tailed) was performed using Microsoft
Excel 2007. Statistical significance was defined as p,0.05.
Statistical correlation tests between the
clinicopathological features of the cat mammary lesions,
detected sequence variants, and IHC and qRT-PCR results
For this analysis, we calculated two values: Pearson’s correlation
coefficient (measure of linear association) and Spearman’s rho
coefficient (quantitative variables or variables with ordered
categories). Correlations were considered to be significant at
p-values of 0.05 (5% significance) and 0.01 (1% significance),
respectively. Correlation coefficients obtained with less than 5
match values were not considered in the final analysis. The data
was analysed assuming that, for each clinicopathological charac-
teristic, a higher value corresponded to a worse prognostic/clinical
evaluation (Table S2). We completed our study with a bivariate
correlation analysis between the different clinicopathological
features of the cat mammary lesions with RNA expression levels
and immunohistochemical scores (Table S6). The correlation test
with the SVs detected, was performed only with the clinicopath-
ological features (Table S7).
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Supporting Information
Figure S1 ERBB2 DNA partial sequence corresponding
to exons 10–15 align study. Multi-alignment between
reference (Cat ERBB2 DNA 10–15) and variant (Cat ERBB2
DNA 10–15 variant) cat ERBB2 DNA sequences and the
corresponding Human ERBB2 variant 2 mRNA sequence
(Human ERBB2 mRNA 10–15). The genomic SVs are black
highlight. (N) Multi-allelic SV present in genomic position 271
(g.271 T.G and g.271 T.A). Adobe (.PDF), Paper size
18645 cm.
(DOC)
Figure S2 Align study of ERBB2 partial coding sequence
corresponding to exons 10–15 transcripts. Multi-alignment
between wild-type sequence (Cat ERBB2 CDS 10–15 wt) and
variant (Cat ERBB2 CDS 10–15 variant) cat ERBB2 cDNA
sequence and the corresponding Human ERBB2 variant 2 mRNA
sequence (Human ERBB2 mRNA 10–15). The cat ERBB2 CDS
sequences were obtained by introns sequences deletion from the
reference and variant sequences (submitted to GeneBank). The
nsSVs detected in CDS are in red. The synonymous SVs detected
in CDS are in green. Adobe (.PDF); paper size A4.
(DOC)
Figure S3 Align study of ErbB-2 partial protein se-
quence corresponding to exons 10–15 translation. Multi-
alignment between wild-type (Cat erbB-2 10–15 protein wt) and
variant cat erbB-2 protein sequence and with the corresponding
Human erbB-2 partial protein sequence. The Human sequence
correspond to part of the chain A from the 3BE1 model. The
amino-acid changes detected are indicated in red. Adobe (.PDF);
paper size 21615 cm.
(DOC)
Figure S4 Western blot with the CBE356 and CB11 anti-
erbB2 antibodies. Reactivity observed by western immunoblot
with the CBE356 and CB11 anti-erbB2 antibodies, in 3 feline
mammary tissues. Lane 1: non-neoplastic cat mammary tissues;
Lanes 2-3: cat mammary lesion samples. The expected molecular
weight (185 kDa) of the reactive protein band, was determined by
comparison, with the molecular weights of the standard Protein
Marker (PM). Adobe (.PDF); paper size 21615 cm.
(PDF)
Figure S5 ERBB2 DNA copy number quantification:
standard curve construct and copy number/haploid
genome assessment. (A) Standard curve constructed with a
2-fold serial dilution series of the plasmid DNA with the ERBB2
insert, ranging from 3.126107 to 1.956106 copies (5 points series
dilutions, each point in triplicate). The Efficiency of the PCR
reaction was 98% (R2 = 0.996). (B) 10 normal and 10 mammary
lesions were subjected to real time quantitative PCR for gene copy
number evaluation. In all cases we didn’t detect any gene
amplification. (IHC) Immunohistochemistry. Adobe (.PDF);
paper size 21615 cm.
(PDF)
Table S1 Summary of the clinicopathological evaluation
and clinical outcome of the cat mammary benign,
malign and metastatic lesions study in the present
work. Tumour identification (ID) in 3 categories: (BL) benign
lesions; (MaL) primary malign lesion; (MeL) metastasis lesion.
(neo) neoplastic; (hip) hyperplasia; (LN) Lynph node; (rec)
recurrence; (NE) No evidence; (NA/E) Not applicable/evaluated.
Clinical outcome evaluation: (DOD) dead of disease; (DC)
developed a carcinoma (NED): no evidence of the disease;
(*NED) no evidence of the disease for more than 2 years;
(DOC) dead of other causes. (#) Histological classification in
accord with Misdorp et al. (1999) [83]. The evaluation grade is in
accord with Gimenez et al. (2010) [85] and Misdorp W. (2002) [6]
(describe in Table S2). Word (.doc); Page size 33633 cm.
(DOC)
Table S2 Cat mammary lesions clinical and histological
grading evaluation features and other prognostic fac-
tors. Accordingly with Gimenez et al. (2010) (*) [85] and Misdorp,
W. (2002) (#) [6]. The scores grading presuppose that, for each
clinicopathological characteristic, a higher value corresponded to a
worse prognostic/clinical evaluation. Word (.doc); Page size
A4.
(DOC)
Table S3 Analysis of sequence variants detected in the
Cat ERBB2 gene fragment between exons 10 to 15. A total
of 30 SVs were detected with dissimilar observation of 15 SVs in
normal and CML samples. The minor allele and the genotype
heterozygosis frequencies (%) were calculated individually for each
SV. The Hardy-Weinberg equilibrium is indicated by the
frequency value (p-value) calculated by the Chi-square test. The
SVs that present p,0.05 are considered to present HWE
deviation. The probable amino-acid changes are indicated whit
the respective number of the amino-acid in the cat erbB-2_10/15
protein sequence. Two synonymous (Syn.) and five non-Synony-
mous (Non-Syn.) variations were detected in exonic positions. The
zero percentage values were removed for better visualization.
Footnotes: (*) 6 SVs only in normal samples; (#) 9 SVs only in
mammary lesions samples; (a) SVs with significant values of allelic
association with the CMLs; (g) SVs with significant values of
genotypic association with the CMLs. Word (.doc); paper size:
29625 cm.
(DOC)
Table S4 Resume of the AA change effects in cat erbB-2
protein: results of the analysis in Pymol and Polyphen/
Polyphen-2 software’s. (nc) no changes detected. The
categorization results obtained with Polyphen and Polyphen-2
bioinformatics automatic tools are the same. Word (.doc);
paper size A4.
(DOC)
Table S5 Cat erbB-2 immunohistochemical staining
results for each antibody used: CBE356, specific for
the external domain and CB11, specific for the internal
domain. The strength of immunostaining was estimated as
negative (0 and +) or positive (++ and +++). (*) 3 normal mammary
samples from 2 hyperplasia cases; (a) Tubulopapillary carcinomas
with solid, mucinous or different disease stage; (b) Systemic
metastasis; (neo-BL) neoplastic benign lesions; (MaLs) primary
malign lesions. Word (.doc); paper size: 25/40 cm.
(DOCX)
Table S6 Correlation measure between ERBB2 RNA
and erbB-2 protein expression levels and clinicopatho-
logical features of primary mammary lesions. (Red *)
Correlation is significant at the 0.05 level. (Red **) Correlation is
significant at the 0.01 level. (Corr.) Correlation tests Output. (N)
Number of rows in working input data file. (-) Negative
relationship between variables. Two-tailed bivariate correlation
analysis calculated with indication of two significance levels
(p-value not showed). The correlation significant values of the
Pearson’s analysis were confirmed by the Spearman’s test. Word
(.doc); paper size A4.
(DOC)
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Table S7 Correlation measure between cat ERBB2_10–
15 Sequence Variants detected and clinicopathological
features of cat mammary lesions. Two-tailed bivariate
correlation analysis calculated with indication of two significance
levels (p-value not showed). The significant values of the Pearson’s
correlation analysis were confirmed by the Spearman’s test. (*)
Correlation is significant at the 0.05 level. (**) Correlation is
significant at the 0.01 level. (-) negative correlation between the
variables. (a) Cannot be computed because at least one of the
variables is constant. Word (.doc); paper size 40620 cm.
(DOC)
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